use of additives intrathecally to enhance in post operative pain control management

comparison of intrathecal hyperbaric bupivacaine 0.5% with morphine versus dexmedetomidine in infraumbilical surgeries - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082317

Enrollment

180

Registered

2025-03-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Sub Arachnoid Block: for infraumbilical surgery Sub Arachnoid Block using Bupivacaine (0.5%) with additives for post operative pain management Control Intervention1: intrathecal Morphin

Eligibility

Inclusion criteria

Inclusion criteria: patient giving consent patient under ASA I and ASA II

Exclusion criteria

Exclusion criteria: 1.Patients with pre-existing respiratory, cardiac, diabetes mellitus, neurological disorders, hepatic or renal disease 2. Patient having local infection at the site of Subarachnoid block (SAB) 3. Patient on anticoagulant therapy 4. Patient with raised Intracranial pressure (ICP) 5. Patients with spinal abnormalities 6. Those with contraindications for spinal anesthesia 7. Patient with known case of bradycardia, hypotension and drug allergy

Design outcomes

Primary

Measure	Time frame
to compare the effects of intrathecal hyperbaric bupivacaine 0.5% with morphine versus dexmedetomidine by determining the duration of analgesia in infraumbilical surgeriesTimepoint: 24 hrs	—

Secondary

Measure	Time frame
any adverse effectsTimepoint: 24 hrs	—

Countries

India

Contacts

Public ContactA.K Sinha

GMC Haldwani

sinhaak1961@gmail.com9897672301

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026